Related Experiment Video
Updated: Mar 23, 2026

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes
Published on: July 7, 2023
The future of intravenous iron in nephrology
1Department of Medicine , Washington University School of Medicine , St. Louis, MO USA.
Abstract:
Management of anaemia in chronic kidney disease (CKD) patients can be difficult and expensive. The recently completed Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT), the largest double-blinded trial of erythropoiesis-stimulating agents (ESA) treatment in CKD to date, provides us with a wealth of new information on the natural history of anaemia in Stage 3 and 4 CKD and the risks and benefits of use of ESAs. This section will discuss some of the TREAT trial results in the context of other recent studies of ESAs and intravenous iron in CKD patients. It will also review applying those results when choosing anaemia goals for an individual, and determining if iron therapy might improve anaemia.
More Related Videos
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury VI: Nursing Management
Hemodialysis III: Nursing Management
Chronic Kidney Disease IV: Nursing Management
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

